Pneumococcal Disease Prevention Among Adults Strategies for the Use of Pneumococcal Vaccines
Pneumococcal Disease Prevention Among Adults Strategies for the Use of Pneumococcal Vaccines
复制标题
DOI：
10.1016/j.amepre.2015.09.008
复制
发表时间：
2015-12-01
影响因子：
5.5
通讯作者：
Bennett, Nancy M.
中科院分区：
文献类型：
--
作者：
Pilishvili, Tamara;Bennett, Nancy M.
自2000年以来，在美国儿童中使用肺炎球菌结合疫苗极大地减少了成年人的肺炎球菌疾病负担。肺炎球菌感染的显著的疫苗可预防的发病率和死亡率仍然存在，特别是在老年人中。美国免疫实践咨询委员会(ACIP)最近建议65岁的成年人常规使用肺炎球菌结合物(PCV13)和多糖疫苗(PPSV23)。这些建议是基于成年人的剩余疾病负担和预防非细菌性肺炎的重要性，因为新的证据证实了PCV13对预防老年人肺炎球菌肺炎的有效性。本文回顾了ACIP建议成人使用PCV13和PPSV23的证据，并强调了未来研究需要解决的潜在差距，以便为成人疫苗接种政策提供信息。应密切监测侵袭性肺炎和肺炎的不断变化的流行病学，以评估当前疫苗接种战略的有效性和持续有效性，并确定未来在老年人中预防肺炎球菌疾病的方向。(C)2015年，由美国预防医学杂志和爱思唯尔有限公司出版。版权所有。
Use of the pneumococcal conjugate vaccines among children in the U.S. since 2000 has dramatically reduced pneumococcal disease burden among adults. Significant vaccine-preventable morbidity and mortality from pneumococcal infections still remains, especially among older adults. The U.S. Advisory Committee on Immunization Practices (ACIP) has recently recommended the routine use of both pneumococcal conjugate (PCV13) and polysaccharide vaccines (PPSV23) for adults >= 65 years. These recommendations were based on the remaining burden of illness among adults and the importance of non-bacteremic pneumonia prevention in light of new evidence confirming the efficacy of PCV13 to prevent pneumococcal pneumonia among older adults. This paper reviews the evidence that led ACIP to make recommendations for PCV13 and PPSV23 use among adults, and highlights potential gaps to be addressed by future studies to inform adult vaccination policy. The changing epidemiology of invasive pneumococcal disease and pneumonia should be closely monitored to evaluate the effectiveness and continued utility of the current vaccination strategy, and to identify future directions for pneumococcal disease prevention among older adults. (C) 2015 by American Journal of Preventive Medicine and Elsevier Ltd. All rights reserved.